Ultralife Corporation reported a decrease in revenue for the fourth quarter, primarily due to the negative economic impact of the global pandemic. However, the company saw growth in medical and government/defense sales, which partially offset the decline. The company's operating results were in line with internal expectations.
GAAP EPS was $0.13, and Adjusted EPS was $0.17.
Revenue was $29.0 million, a decrease of 6.6% compared to the same quarter last year.
Battery & Energy Products medical sales were up 94% and government/defense sales were up 19%.
The company recognized a $1.6 million gain upon resolution of a claim in a class action lawsuit.
While the outlook for demand in our end markets is less visible than we would like, we will remain focused on what we can control: organic growth initiatives, including completing transformational new product development projects and investments in strategic capital expenditure, and synergistic acquisitions.